Arno Therapeutics brings in US$7.4mln to advance breast cancer treatment

Arno Therapeutics brings in US$7.4mln to advance breast cancer treatment

The drug, originally developed by Schering AG, has shown a 56% objective response rate as a first-line endocrine treatment for breast cancer. In addition, the funds will be used for working capital. The financing includes around US$2.1mln from the

(Visited 3 times, 1 visits today)
7
Like
Save

Comments

Comments are disabled for this post.